- Report
- February 2026
- 250 Pages
Global
From €4052EUR$4,490USD£3,520GBP
- Report
- October 2025
- 146 Pages
Global
From €4422EUR$4,900USD£3,842GBP
- Report
- October 2025
- 100 Pages
Global
From €4377EUR$4,850USD£3,803GBP
- Report
- March 2026
- 529 Pages
Global
From €6313EUR$6,995USD£5,484GBP
- Report
- April 2025
- 171 Pages
Global
From €4422EUR$4,900USD£3,842GBP
- Report
- October 2025
- 120 Pages
Global
From €5370EUR$5,950USD£4,665GBP
- Report
- September 2025
- 130 Pages
Global
From €5370EUR$5,950USD£4,665GBP
- Report
- January 2026
- 181 Pages
Global
From €3199EUR$3,545USD£2,780GBP
€3555EUR$3,939USD£3,088GBP
- Report
- January 2026
- 186 Pages
Global
From €3199EUR$3,545USD£2,780GBP
€3555EUR$3,939USD£3,088GBP
- Report
- January 2026
- 183 Pages
Global
From €4061EUR$4,500USD£3,528GBP
- Report
- January 2026
- 181 Pages
Global
From €4061EUR$4,500USD£3,528GBP
- Report
- February 2026
- 250 Pages
Global
From €4052EUR$4,490USD£3,520GBP
- Report
- February 2026
- 250 Pages
Global
From €4052EUR$4,490USD£3,520GBP
- Report
- February 2026
- 250 Pages
Global
From €4052EUR$4,490USD£3,520GBP
- Report
- February 2026
- 250 Pages
Global
From €4052EUR$4,490USD£3,520GBP
- Report
- March 2026
- 380 Pages
Global
From €5279EUR$5,850USD£4,587GBP
- Report
- March 2026
- 479 Pages
Global
From €5279EUR$5,850USD£4,587GBP
- Report
- March 2026
- 478 Pages
Global
From €5279EUR$5,850USD£4,587GBP
- Report
- March 2026
- 217 Pages
Global
From €5279EUR$5,850USD£4,587GBP
- Report
- March 2026
- 194 Pages
Global
From €5279EUR$5,850USD£4,587GBP

The Cancer Liquid Biopsy market is a subset of the Diagnostics industry that focuses on the use of liquid biopsies to detect and monitor cancer. Liquid biopsies are non-invasive tests that use a sample of blood, urine, or other bodily fluid to detect cancer cells or genetic material associated with cancer. This type of biopsy can provide information about the type and stage of cancer, as well as the presence of mutations that may affect treatment options. Liquid biopsies are increasingly being used to monitor cancer progression and response to treatment, as well as to detect cancer recurrence.
Some companies in the Cancer Liquid Biopsy market include Guardant Health, Exosome Diagnostics, Freenome, and Biocept. Show Less Read more